Fondo Bibliografico Internacional Mayo 2005
4.- Enfermedad hepática alcohólica,
hígado graso y esteatohepatitis no alcohólica.
A randomized controlled trial of metformin versus vitamin E
or prescriptive diet in nonalcoholic fatty liver disease. Bugianesi E, Gentilcore
E, Manini R, Natale S, Vanni E, Villanova N, David E, Rizzetto M, Marchesini
G. American Journal of Gastroenterology 2005;100:1082-90.
La metformina produce mejores efectos beneficiosos
que la vitamina E o la dieta en la esteatosis no alcohólica.
One-year intense nutritional counseling results in histological
improvement in patients with non-alcoholic steatohepatitis: a pilot study.
Huang MA, Greenson JK, Chao C, Anderson L, Peterman D, Jacobson J, Emick D,
Lok AS, Conjeevaram HS. American Journal of Gastroenterology 2005;100:1072-81.
Notable tasa de respuesta histologica favorable tras
tratamiento dietético en los pacientes con esteatohepatitis no alcohólica.
Activity of CYP2E1 and CYP3A enzymes in adults with moderate
alcohol consumption: a comparison with nonalcoholics. Liangpunsakul S, Kolwankar
D, Pinto A, Gorski JC, Hall SD, Chalasani N. Hepatology 2005;41:1144-50.
El consumo moderado de alcohol no modifica sustancialmente
la actividad microsomal hepatica aunque puede aumentar la actividad intestinal.
Elevated plasma protein C levels correlate with the presence
of fatty liver (NASH and NAFLD). Assy N, Schlesinger S, Hussein O. Gut 2005;54:729.
Carta.
The prevalence of autoantibodies and autoimmune hepatitis in
patients with nonalcoholic fatty liver disease. Loria P, Carulli N, Lonardo
A. American Journal of Gastroenterology 2005;100:1200-1.
Carta.
MELD score is a better prognostic model than Child-Turcotte-Pugh
score or Discriminant Function score in patients with alcoholic hepatitis.
Srikureja W, Kyulo NL, Runyon BA, et al. Journal of Hepatology 2005;42:700-6.
Superioridad del MELD con respecto al Chid-Pugh y
a la función discriminante de Maddrey en la predicción de mortalidad
hospitalaria en pacientes con hepatitis alcohólica.
Hepatic phospholipids in alcoholic liver disease assessed by
proton-decoupled (31)P magnetic resonance spectroscopy. Schlemmer HP, Sawatzki
T, Sammet S, et al. Journal of Hepatology 2005;42:752-9.
Resonancia magnética espectroscópica
hepática en el diagnóstico de las alteraciones del metabolismo
fosfolipídico en pacientes con hepatopatía alcohólica.
Late complications of NASH: a challenge for hepatologists.
Bugianesi E. Journal of Hepatology 2005;42:784-5.
Editorial.
Pathogenesis of primary nonalcoholic fatty liver disease. Moreno
Sanchez D. Medicina Clinica 2005;124:668-77.
Revisión.
